Home > Boards > US Listed > Biotechs > REATA PHARMACEUTICALS INC [ RETA ] (RETA)

Reata Pharmaceuticals, Inc. Appoints Dawn Carter Bir as

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Cbdpotential Member Profile
 
Followed By 251
Posts 16,111
Boards Moderated 1
Alias Born 03/28/13
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/17/2019 4:52:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/16/2019 4:24:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/15/2019 4:04:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/15/2019 3:53:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2019 6:48:53 AM
Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s... GlobeNewswire Inc. - 10/14/2019 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/11/2019 4:47:49 PM
Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019 GlobeNewswire Inc. - 10/11/2019 10:00:00 AM
Reata Pharmaceuticals Shares Up 8% on Re-Acquiring Bardoxolone Rights Dow Jones News - 10/10/2019 12:41:00 PM
Reata Pharmaceuticals Reacquires Rights to Bardoxolne Dow Jones News - 10/10/2019 7:49:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/10/2019 6:52:10 AM
Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All N... GlobeNewswire Inc. - 10/10/2019 6:45:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/30/2019 3:19:06 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 9/25/2019 2:09:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2019 12:27:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/10/2019 3:46:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/29/2019 4:21:33 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/29/2019 4:17:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/29/2019 6:01:59 AM
Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations GlobeNewswire Inc. - 8/28/2019 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/22/2019 4:55:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/16/2019 3:09:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/8/2019 6:51:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/8/2019 6:45:52 AM
Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs GlobeNewswire Inc. - 8/8/2019 6:40:00 AM
Cbdpotential   Tuesday, 10/11/16 09:38:22 AM
Re: None
Post # of 53 
Reata Pharmaceuticals, Inc. Appoints Dawn Carter Bir as Vice President and Chief Commercial Officer

Source: GlobeNewswire Inc.

Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Dawn Carter Bir as Vice President and Chief Commercial Officer.
Ms. Bir joins the company with over 20 years of biopharmaceutical sales and marketing experience. Over the past decade she served in senior leadership roles at Pharmacyclics, LLC, McKesson Corporation, and Genentech, Inc. Most recently, Ms. Bir served as Vice President of US Sales at Pharmacyclics, LLC where she built and led their first hematology national sales organization of sales representatives, division managers, and regional sales directors, responsible for the launch of IMBRUVICA in the US and Puerto Rico. In only 18 months, her team became an industry-recognized commercial sales presence and executed a history-making oncology launch. Prior to joining Pharmacyclics, LLC, Dawn served as Vice President Sales & Marketing with McKesson US Pharmaceutical, SKY Pharmaceuticals, and RxPak.

“We are pleased to welcome Dawn to the role of Chief Commercial Officer,” said Warren Huff, Reata’s Chief Executive Officer and President. “Dawn is an experienced executive with a proven ability to build and lead sales and marketing organizations. She is also ideally suited to orchestrate our anticipated product launches and collaborate effectively with our global commercial partners.”

Ms. Bir received a B.S. in Biology from Binghamton University, Binghamton, NY.

About Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular energy production and inflammation. Our two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target important transcription factors, called Nrf2 and NF-?B, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Forward-Looking Statements

This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including its Registration Statement on Form S-1, as amended from time to time, under the caption “Risk Factors.” The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


Contact:
Reata Pharmaceuticals, Inc.
(972) 865-2219
info@reatapharma.com
http://reatapharma.com

Investor Relations:
The Trout Group
Lee M. Stern, CFA
(646) 378-2922
IR@reatapharma.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist